Highlights AstraZeneca PLC Nasdaq Stockholm

Equities

AZN

GB0009895292

Real-time Estimate Cboe Europe Other stock markets 06:51:35 27/06/2024 pm IST			5-day change	1st Jan Change
1,674 ^SEK	-0.03%		+1.86%	+23.72%

12:39pm	US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	RE
26/06	European Equities Close Lower in Wednesday Trading	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	04:09pm	RE
European Equities Close Lower in Wednesday Trading	26/06	MT
AstraZeneca Wins Chinese Regulatory Nod for Lung Cancer Combination Treatment	26/06	MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws	25/06	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	25/06	MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	25/06
AstraZeneca Says Imfinzi With Chemotherapy Improves Survival in Phase 3 Bladder Cancer Trial	25/06	MT
AstraZeneca's Tagrisso Approved With Chemotherapy in Japan for Lung Cancer Treatment	25/06	MT
AstraZeneca Says Phase 3 Imfinzi Trial in Early-Stage Lung Cancer Misses Primary Endpoint	25/06	MT
AstraZeneca Logs Hit and Miss in Oncology Drugs Portfolio	25/06	MT
AstraZeneca PLC Announces IMFINZI Demonstrates Statically Significant and Clinically Meaningful Improvement in Event-Free Survival and Overall Survival for Muscle-Invasive Bladder Cancer in Niagara Phase III Trial	25/06	CI
AstraZeneca's Imfinzi fails in late-stage trial to treat certain lung cancers	25/06	RE
AstraZeneca: inconclusive trial for Infinzi in NSCL	25/06	CF
AstraZeneca: inconclusive trial for Infinzei in NSCL	25/06	CF
AstraZeneca details mixed findings from cancer drug trials	25/06	AN
Correction: AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	25/06	MT
AstraZeneca's Tagrisso Combo Wins Approval as First-line Lung Cancer Treatment in Japan	25/06	MT
AstraZeneca's Adjuvant Lung Cancer Drug Fails to Improve Disease-free Survival in Late-stage Trial	25/06	MT
AstraZeneca's Imfinzi Gets Positive Results in Bladder Cancer Trial	25/06	DJ
Mixed bag for Astra drug; Landsec ups Bluewater stake	25/06	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 09:32 pm IST